On March 16-17, Moscow hosted the Healthy Life Forum, a leading platform for dialogue and solutions aimed at increasing healthy life expectancy, strengthening mental well-being, and creating a supportive environment. At the Medtech Moscow booth, the NeurOmix project was presented — an omics platform for diagnosing the risk of mental disorders developed at Skoltech’s Neuro Center in collaboration with physicians from the Alekseev Psychiatric Clinical Hospital No. 1.

Currently, psychiatric diagnosis relies primarily on the clinical-psychopathological method, which involves interviewing and observing the patient. However, the conclusions largely depend on the specialist’s subjective opinion, and diagnosis is often delayed until after the pathological process has already developed. The project aims to introduce additional tools to help both doctors and patients better understand inner processes.

Skoltech researchers and their colleagues applied omics technologies to create the NeurOmix test system. The technology can assess predisposition to mental disorders or confirm their presence through a blood test. The method does not replace the physician but provides additional objective information to support diagnosis. What makes it unique is its analysis of hundreds of lipid compounds in blood plasma.

In 2023, the first testing of the technology took place with support from the Moscow Center for Innovative Technologies in Healthcare and the Alekseev Psychiatric Clinical Hospital No. 1, involving about 1,000 participants. The sample later expanded to nearly 5,000 volunteers. According to the data obtained, the test achieves up to 93% accuracy. Since 2022, the project has received support from the Moscow authorities through a program operated by Medtech.